Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:2.6.1.2 (alanine aminotransferase)
26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We used the previously described [Clin. Chem. 19, 1114 (1973)] and evaluated [Clin. Chem. 19, 1122 (1973)] computer-controlled instrument system for sequential chemical testing to select and perform tests of hepatic status, to aid the clinician in the diagnosis of liver disease. Results for total bilirubin, aspartate aminotransferase, and alkaline phosphatase obtained from the continuous-flow analysis (SMA 12/60) admission screen were used by the instrument system to determine selectively the values for gamma-glutamyltransferase, alanine aminotransferase, creatine kinase, and total and direct bilirubin. Kit methods for the latter four tests were evaluated on the system; results were similar to manual procedures. A software, enzymatic ratemeter was found to be better than the previously described hardware ratemeter. The follow-up tests of serum prescribed by the system are compared to clinician-prescribed follow-up tests and discharge diagnoses. In 10 of 19 cases, the system and clinician ordered similar follow-up tests; in three cases follow-up differed, and in six cases, the system ordered follow-up tests and the clinician ordered none.
...
PMID:Computer-controlled instrument system for sequential chemical testing III. Application to liver assessment. 34 61

A prospective longitudinal study was performed in 48 patients with acute hepatitis B (AHB) of whom 38 were previously healthy (PH) and 10 drug addicted (DA). Smooth muscle antibody was present in 23/38 PH and in 8/10 DA patients for a median of 4 weeks; other autoantibodies were not found. In the PH patients SMA was of IgM class in 23/23 and 8/23 of the IgG class as well. In the 8 DA patients 2 had IgM-SMA only, 3 (IgM+IgG)-SMA and 3IgG-SMA only. IgG-SMA presence could not be related to the duration or titer height of SMA nor to the type of fluorescence patterns. In SMA-negative patients IgM-anti-HBc was cleared within 6 weeks and in IgM-SMA positive patients within 32 weeks (medians 4 and 5 weeks) after maximal S-GPT. IgM-anti-HBc persisted for years in 3/3 IgG-SMA positive and in 2/11 IgG-IgM positive patients. In the remaining 9 IgG-IgM SMA positive patients it disappeared within 15 (median 9) weeks after maximal S-GPT. All 34 patients without SMA or with IgM-SMA only recovered completely. The 3 patients with IgG-SMA and 2 of the 11 patients with IgG+IgM SMA developed chronicity. Determination of SMA and of its immunoglobulin classes, at maximal SGPT may in acute hepatitis B be of help in predicting the outcome of disease.
...
PMID:Immunoglobulin classes of smooth muscle antibody in the course of acute hepatitis B: prognostic significance. 72 11

We report the evaluation of a novel clinical chemical analyser, the OLLI CD, which is highly automated compared to its predecessor, the OLLI 3000 analyser. The precision of the dispensing unit, the OLLI D, was assessed with the aid of aqueous solutions of 131I. Sample pipetting of 10 microliter resulted in a coefficient of variation of 0.81%. Lower volumes were unreliable. However, precision of the addition of start reagent for kinetic methods appeared to be only 2.7% for 20 microliter, 1.7% for 50 microliter and 2.1% for 250 microliter. The linearity of response and the precision of the photometer unit, the OLLI C, was assessed with cobalt(II)sulfate solutions. The linearity ranged up to an absorbance of 2.5. The reproducibility of the colorimeter ranged from A510nm 0.0011 to 0.0047. With this analyser good correlations were obtained for alanine aminotransferase (EC 2.6.1.2) vs LKB 8600 reaction rate analyser; for creatinine vs Mark II Autoanalyzer; and for total protein vs SMA 6/60 Autoanalyzer. These three determinations showed acceptable between-day variations. General instrument performance was acceptable.
...
PMID:An evaluation of the automated OLLI CD discrete analyser. 731 Mar 22

We prospectively measured serum alkaline phosphatase (ALP), aspartate and alanine transaminase (AST/ALT), and tested sera for antinuclear, smooth-muscle, and antimitochondrial antibodies (ANA, SMA, AMA) in our patients with celiac sprue to determine the prevalence of associated liver abnormalities and its relevance to clinical management. Of 129 patients, ALP was the only elevated enzyme in 12 (9%) and in most cases was not thought to reflect significant liver disease. Seventeen (13%) had elevated AST and/or ALT with normal ALP. Levels normalized in 15 patients after dietary gluten exclusion and remained elevated in 2 noncompliers. Two patients (2%) with elevated AST, ALT, and ALP underwent further investigation: one had negative autoantibodies, liver biopsy, and endoscopic retrograde cholangiography and the other had ANA-positive chronic active hepatitis; enzymes in both cases improved with a gluten-free diet. There was no significant association between elevated AST/ALT and positive ANA/SMA; no patient had AMA. Abnormalities in liver enzymes are common in celiac sprue, but usually respond to dietary gluten exclusion. We propose that there is no need for invasive liver investigation in these patients unless there is more specific evidence of primary liver disease or failure of dietary response.
...
PMID:Liver abnormalities associated with celiac sprue. How common are they, what is their significance, and what do we do about them? 766 16

Interferon (IFN) has become the standard therapy for chronic hepatitis C. The use of IFN should be accompanied by adequate diagnosis and management using standard practices as well as new and sophisticated techniques now available. A liver biopsy performed prior to IFN therapy initiation remains the standard for adequate histological diagnosis of HCV disease as well as determination of disease severity and the presence of liver cirrhosis. ALT normalization is not adequate to determine complete short-term response to IFN treatment. Adverse effects resulting from IFN therapy include a flulike syndrome, hematologic effects, neuropsychiatric effects, and thyroid abnormalities. The majority of these can be adequately managed without discontinuation of IFN treatment. However, preexisting psychiatric conditions are a contraindication to IFN therapy. IFN treatment also is contraindicated in patients with autoimmune hepatitis (AIH). Therefore, it is important to distinguish AIH from chronic HCV infection using HCV-RNA analysis and determination of autoimmune titers (including anti-LKM antibodies, anti-SMA, and ANA). Recently reported adverse effects of IFN include respiratory and ocular effects. Serological diagnosis of HCV infection has evolved to the use of second- and third-generation ELISA tests. Although sophisticated, these tests cannot distinguish between active and quiescent infection, and therefore are of limited value in monitoring treatment response. Several other techniques have been suggested: the ratio between IgG and IgM class anti-HCV core antibodies, detection of antibodies against a glycosylated recombinant product of the E2 envelope glycoprotein, and several different polymerase chain reaction (PCR) techniques. The latter appears to be the most promising. Use of these techniques should be incorporated into the monitoring of IFN therapy to assist in the evaluation of adequate treatment response, the need for treatment alteration, and estimation of relapse risk upon treatment cessation.
...
PMID:Managing patients on interferon therapy. 901 69

The effects of diltiazem on an experimental study of Superior Mesenteric Artery ligation were studied on three rat groups comprising controls (N = 5), SMA ligation (N = 8), and SMA ligation and diltizem (0.25 mg/kg injection), (N = 8). Creatine phosphokinase, lactic dehydrogenase, aspartate transaminase and alanine transaminase venous blood levels were significantly decreased after diltiazem injection compared with the SMA ligation group. Histopathologic examinations revealed that diltiazem partly protected the small intestine from ischemic changes.
...
PMID:The effects of diltiazem on superior mesenteric artery ligation. An experimental study. 912 98

Antibodies to nuclei (ANA), smooth muscle (SMA), and liver/kidney microsomes type 1 (anti-LKM1) may occur in chronic hepatitis C. Distinct subspecificities, including ANA with the homogeneous pattern (ANA-H) and SMA with antiactin specificity (SMA-AA), are found in autoimmune hepatitis (AIH). This study was performed to characterize the hepatitis C virus (HCV)-associated autoantibodies and to evaluate their influence on the profile of the disease. Two hundred ninety consecutive patients with chronic hepatitis C and 35 control cases with AIH were screened for autoantibodies by indirect immunofluorescence (IFL) at 1:40 serum dilution. The ANA pattern was defined by IFL on HEp-2 cells and the SMA-AA identified by the presence of at least two of the following elements: 1) SMA(T) or SMA(G) pattern by IFL on kidney sections; 2) XR1 precipitating system by counterimmunoelectrophoresis; or 3) typical pattern by IFL on liver sections from phalloidin-intoxicated rats. ANA, SMA, and anti-LKM1 occurred in 9%, 20%, and 6% of chronic hepatitis C cases, respectively. The overall prevalence of autoantibodies was 30% (87 of 290). Compared with AIH, HCV-associated ANA and SMA exhibited ANA-H and SMA-AA at a lower prevalence (38% vs. 71%, P = .04 and 8% vs. 87%, P < .000001, respectively) and had a lower median titer (1:80 vs. 1:320, P < .001 and 1:40 vs. 1:320, P < .000001, respectively). The concomitant positivity for ANA-H and SMA-AA was detected in none of the HCV cases, but in 46% of AIH sera (P < .000001). Two parameters were independently associated with the autoantibodies in chronic hepatitis C: high alanine transaminase (ALT) serum levels (F = 14.04) and female gender (F = 5.03). At the univariate analysis, patients with autoantibodies had a more severe portal-periportal necroinflammation (median Scheuer's score: 2.05 vs. 1.64, P = .003). The presence of autoantibodies did not influence the response to interferon (IFN). In chronic hepatitis C, serum autoantibodies are common, but their subspecificities are distinct from those occurring in AIH. Whereas the absence of ANA-H and/or SMA-AA does not exclude AIH, the characterization of ANA and SMA may help to discriminate between the two conditions. As compared with the seronegative counterpart, autoantibody-positive chronic hepatitis C is more common in females and exhibits a more severe biochemical and histological activity. The response to IFN therapy, however, is similar.
...
PMID:Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. 958 9

The aim of this study was to determine the incidence of autoantibodies to asialoglycoprotein receptor (ASGPR, anti-ASGPR) in chronic hepatitis C patients and to characterize the anti-ASGPR-positive and anti-ASGPR-negative patients in more detail. A total of 79 chronic hepatitis C patients were screened for the presence anti-ASGPR by ELISA. Anti-ASGPR were detected in 11 (13.9%) patients. No significant differences were found between the anti-ASGPR-positive and anti-ASGPR-negative patients in age, alanine transaminase (ALT) activity, histological findings and response and tolerance to alpha-interferon (alpha-IFN) therapy. The male predominance in the anti-ASGPR positive group was statistically significant. It was surprising that other tested autoantibodies (antinuclear autoantibodies [ANA], smooth muscle autoantibodies [SMA], type 1 liver-kidney microsome autoantibodies [LKM-1], anti-thyroglobulin and thyroid microsome autoantibodies) and increased levels of immunoglobulins A, G and/or M were observed significantly more frequently in the anti-ASGPR-negative group.
...
PMID:Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients. 1139 82

AIM:To investigate effect of losartan, an AT1 receptor antagonist, on hepatic fibrosis induced by CCl(4); and to determine whether or not AT1 receptors are expressed on hepatic stellate cells. METHODS AND RESULTS:Fifty male Sprague-Dawley rats, weighing (180 plus minus20)g, were randomized into five groups (control group, model group, and three losartan treated groups), in which all rats were given the subcutaneous injection of 40% CCl(4)(every 3 days for 6 weeks) except for rats of control group. Rats of losartan-treated groups were treated with losartan (20 mg/kg, 10 mg/kg, 5 mg/kg, daily gavage). After 6 weeks liver tissue and serum samples of all rats were examined. Serum hyaluronic acid (HA), procollagen type III (PC III) were detected by radioimmunoassays. van Giesion collagen staining was used to evaluate the extracellular matrix of rats with liver fibrosis. The expression of AT1 receptors, transforming growth factor-beta (TGF-beta), and alpha-smooth muscle actinalpha-SMA) in liver tissue were determined by immunohistochemical techniques. Compared with model group, serum ALT and AST of losartan-treated groups were significantly reduced (italic>t = 4.20,P < 0.01 and italic>t = 4.57,P < 0.01). Serum HA and PC III also had significant differences (italic>t = 3.53,P<0.01 and t=2.20, P<0.05). The degree of fibrosis was improved by losartan and correlated with the expressions of AT1 receptors, TGF-beta, and alpha-SMA in liver tissue.CONCLUSION:AT1 receptor antagonist, losartan, could limit the progression of the hepatic fibrosis induced by CCl(4). The mechanism may be related to the decrease in the expression of AT1 receptors and TGF-beta, ameliorating the injury of hepatocytes; activation of local renin-angiotensin system might relate to hepatic fibrosis; and during progression of fibrosis, activated hepatic stellate cells might express AT1 receptors.
...
PMID:Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). 1181 43

Fibrosis-related changes in livers of cirrhotic rats induced by dimethylnitrosamine (DMN) have not yet been fully clarified. The aim of this study was to investigate changes in molecular and biochemical markers in DMN-intoxicated rats. DMN was administered to Sprague-Dawley rats for 2 and 5 weeks to induce different degrees of hepatic fibrosis. Liver tissues were assessed for the degree of fibrosis and gene expression. Histological examination of the liver showed a progressive increase in fibrosis scores (1.33 +/- 0.21 and 3.03 +/- 0.29, respectively) and expansion of fibrous septa with collagen-staining fibers in rats after 2 and 5 weeks of DMN administration. Hepatic protein contents of alpha-smooth muscle actin (alpha-SMA) and total collagen were significantly higher in rats administered DMN for both 2 and 5 weeks compared with those in control rats. Hepatic mRNA expressions of alpha-SMA, transforming growth factor-beta1 (TGF-beta1), connective tissue growth factor, tissue inhibitor of metalloproteinase-1, and procollagen I and III were increased in DMN rats after 2 and 5 weeks. Abnormal increases in plasma alanine transaminase (ALT) and aspartate transaminase (AST) levels, plasma and mitochondrial MDA levels, and portal venous pressure were also noted in DMN rats. DMN administration to rats for 2 and 5 weeks induced progressive increases in hepatic fibrosis scores, hepatic mRNA expressions of TGF-beta1 and procollagen I and III genes, plasma levels of ALT and AST, and portal venous pressure, as well as progressive decreases in both liver and body weights. Our results suggest that DMN administration in rats induces biochemical and molecular changes related to fibrogenesis in the liver.
...
PMID:Increases in fibrosis-related gene transcripts in livers of dimethylnitrosamine-intoxicated rats. 1506 25


1 2 3 4 5 6 7 8 9 10 Next >>

---